Selective inhibition of mTORC1 by folliculin (FCLN) deletion protects against NASH by TFE3 transcription factor-induced inhibition of lipogenesis (412); however, the impact of FCLN deletion has not been investigated in atherosclerotic mice. The gene discussed is FLCN; the disease is metabolic dysfunction-associated steatohepatitis.